Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-titration study of ISIS 494372 in patients with high lipoprotein(a)
NL-OMON42290Phase 2Active, not recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jan 2015
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ISIS-APO(a)Rx in hyperlipoproteinemia (4 cohorts), sponsored by Ionis Pharmaceuticals. Primary endpoints: Serum lipoprotein(a) levels and Safety and tolerability. Started Jan 2015; status: active, not recruiting.
02
Drugs
ISIS-APO(a)Rx
03
Conditions
hyperlipoproteinemia
Beyond the preview
Go deeper on NL-OMON42290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42290.